Oxford–AstraZeneca COVID-19 vaccine efficacy

Type Journal Article Author Maria Deloria Knoll Author Chizoba Wonodi URL https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32623-4/abstract Series Comment Publication The Lancet ISSN 0140-6736, 1474-547X Date 08/12/2020 Extra Publisher: Elsevier PMID: 33306990 Journal Abbr The Lancet DOI 10.1016/S0140-6736(20)32623-4 Library Catalog www.thelancet.com Language English Abstract 2020 has been a difficult year for all, but has seen 58 vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) be developed and in clinical trials,1 with some vaccines reportedly having more than 90% efficacy against COVID-19 in clinical trials. This remarkable achievement is much-needed good news as COVID-19 cases are currently at their highest daily levels globally.2 New vaccine efficacy results are reported now in The Lancet: investigators of four randomised, controlled trials conducted in the UK, South Africa, and Brazil report pooled results of an interim analysis of safety and efficacy against COVID-19 of the Oxford–AstraZeneca chimpanzee adenovirus vectored vaccine ChAdOx1 nCoV-19 (AZD1222) in adults aged 18 years and older.